For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...